Colucid Pharmaceuticals, Inc. (CLCD): Raymond Skwierczynski , Head,Pharmaceutical Operations of Colucid Pharmaceuticals, Inc. sold 508 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $9.10 per share for a total value of $4,622.80 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Thomas P. Mathers (Chief Executive Officer) sold 1,502 shares at $9.73 per share price.On Jun 30, 2016, Raymond Skwierczynski (Head,Pharmaceutical Operations) sold 516 shares at $7.01 per share price.Also, On May 12, 2015, A/s Novo (10% owner) purchased 1,300,000 shares at $10.00 per share price.
Shares of CoLucid Pharmaceuticals Inc (CLCD) ended Monday, Jul 11, 2016 session in red amid volatile trading. The shares closed down -0.03 points or -0.33% at $9 with 33,501 shares getting traded. Post opening the session at $9.1, the shares hit an intraday low of $8.73 and an intraday high of $9.26 and the price vacillated in this range throughout the day. The company has a market cap of $137 M and the number of outstanding shares has been calculated to be 1,52,75,438 shares. The 52-week high of CoLucid Pharmaceuticals Inc is $10.04 and the 52-week low is $3.57.
CoLucid Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate Lasmiditan for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.